Research programme: macromolecular drug conjugates - Prolynx

Drug Profile

Research programme: macromolecular drug conjugates - Prolynx

Alternative Names: Dual receptor agonists - Prolynx; Hydrogel-exenatide - Prolynx; Hydrogel-octreotide - Prolynx; PEG-exenatide - Prolynx; PEG-octreotide - Prolynx; PLX 039

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Prolynx
  • Class Camptothecins; Drug conjugates; Polyethylene glycols
  • Mechanism of Action DNA topoisomerase I inhibitors; Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists; Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Acromegaly; Cancer; Type 2 diabetes mellitus

Highest Development Phases

  • Preclinical Cancer; Ear disorders; Obesity; Type 2 diabetes mellitus
  • Research Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • No development reported Acromegaly

Most Recent Events

  • 25 Sep 2017 Prolynx receives SBIR grant from National Institutes of Health for development of dual receptor agonist drug conjugates in Type-2 diabetes mellitus, Non-alcoholic fatty liver disease and Non-alcoholic steatohepatitis
  • 25 Sep 2017 Early research in Non-alcoholic fatty liver disease in USA (SC)
  • 25 Sep 2017 Early research in Non-alcoholic steatohepatitis in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top